Novo Nordisk's new amylin-targeting obesity drug, amycretin, demonstrated significant weight loss in a Phase 1/2 study, with the highest dose group losing an average of 24.3% body weight over 36 weeks. Published results in the Lancet highlighted comparable efficacy across varying doses, a finding that deviates from typical dose-response expectations. Side effects also presented challenges, leaving uncertainty over optimal dosing strategies as the company advances its clinical program. These data, disclosed ahead of presentation at the American Diabetes Association conference, suggest amycretin's potential but underline the complexities of dose optimization in obesity therapeutics.